1832 Asset Management L.P. Acquires 245,212 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• 1832 Asset Management L.P. increased its holdings in Thermo Fisher Scientific by 45.1% in Q1, acquiring an additional 245,212 shares, bringing its total to 788,775 shares valued at approximately $392 million.
• Several hedge funds also bought stakes in Thermo Fisher, resulting in 89.23% of the stock being owned by institutional investors.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43, with the ex-dividend date on September 15th, reflecting an annualized yield of 0.4%.

1832 Asset Management L.P. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 45.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 788,775 shares of the medical research company's stock after buying an additional 245,212 shares during the quarter. 1832 Asset Management L.P. owned 0.21% of Thermo Fisher Scientific worth $392,494,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth approximately $35,000. Finally, Navigoe LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $3.78 during trading hours on Wednesday, hitting $484.70. The stock had a trading volume of 457,397 shares, compared to its average volume of 2,455,922. The stock's 50-day moving average price is $446.71 and its two-hundred day moving average price is $455.47. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $183.03 billion, a price-to-earnings ratio of 28.02, a PEG ratio of 2.62 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock worth $13,603,438 over the last quarter. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Barclays increased their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Argus lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Finally, Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.